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Abstract 
Background: Accurately assessing promising therapeutic interventions for human diseases depends, in part, on 
the reproducibility of preclinical disease models. With the development of transgenic mice, the rapid adaptation of a 
6-OHDA mouse model of Parkinson’s disease that was originally described for the use in rats has come with a lack of 
a comprehensive characterization of lesion progression. In this study we therefore first characterised the time course 
of neurodegeneration in the substantia nigra pars compacta and striatum over a 4 week period following 6-OHDA 
injection into the medial forebrain bundle of mice. We then utilised the model to assess the anti-dyskinetic efficacy of 
recombinant activin A, a putative neuroprotectant and anti-inflammatory that is endogenously upregulated during 
the course of Parkinson’s disease.
Results: We found that degeneration of fibers in the striatum was fully established within 1 week following 6-OHDA 
administration, but that the loss of neurons continued to progress over time, becoming fully established 3 weeks 
after the 6-OHDA injection. In assessing the anti-dyskinetic efficacy of activin A using this model we found that treat-
ment with activin A did not significantly reduce the severity, or delay the time-of-onset, of dyskinesia.
Conclusion: First, the current study concludes that a 3 week duration is required to establish a complete lesion of the 
nigrostriatal tract following 6-OHDA injection into the medial forebrain bundle of mice. Second, we found that activin 
A was not anti-dyskinetic in this model.
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Background
Parkinson’s disease (PD) is a progressive neurodegenera-
tive disorder characterized by the loss of dopaminergic 
neurons in the substantia nigra pars compacta (SNpc), 
leading to a reduction in dopamine availability in the 
striatum. Clinically, this manifests as motor dysfunc-
tion, including tremors, rigidity and bradykinesia [1]. 
l-Dopa treatment still remains the most effective avail-
able therapy to improve these motor symptoms, however 
long-term use leads to the development of debilitating 
l-Dopa-induced dyskinesia’s (LIDs) [2]. At present there 
are few available treatments to reduce the course of LID 
development.
Several toxin-based animal models of PD are available 
to investigate the mechanisms of LID development and 
possible strategies to combat it. The MPTP-lesioned non-
human primate [3, 4] and the 6-OHDA lesioned rat [5, 6] 
are traditionally the most prominent. Although there are 
clear benefits to establishing mouse models, particularly 
the ease at which genetically modified lines can now be 
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developed, initial attempts to establish dyskinesia in mice 
suffered several technical setbacks. In particular, MPTP 
lesioned mice simultaneously exhibited inconsistent 
dopamine depletion and required large doses of l-Dopa 
to develop any dyskinetic behaviours [7, 8], while a LID 
mouse model with a 6-OHDA lesion resulted in mortal-
ity rates of up to 82% [9]. Improvement in mortality rates 
is observed in the 6-OHDA mouse model when the injec-
tion location is shifted from the medial forebrain bundle 
(MFB) to either intrastriatal or intranigral, but this comes 
at the cost of reduced and more variable LID expres-
sion [10]. More recently, these issues have been over-
come by injecting a smaller volume of more concentrated 
6-OHDA into the MFB of mice, which has led to reduced 
mortality rates and more consistent lesions with animals 
expressing stable LIDs [11]. While the behavioural out-
comes have been characterized in detail, the time course 
of neurodegeneration in this updated MFB 6-OHDA 
mouse model has gained less attention. Therefore, we 
first aimed to investigate the progression of neuron loss 
in the SNpc and terminal loss in the striatum over a 
4 week period.
Using this model, our next aim was to then investigate 
a novel pharmacological approach to prevent, reverse 
or halt the development of LIDs. It is by now acknowl-
edged that chronic neuroinflammation may play a role 
in the development of PD pathology [12, 13]. It is also 
well-established that mouse models of PD, including the 
6-OHDA MFB mouse model, recapitulate this phenotype 
[14]. Conceivably, as recently suggested, neuroinflam-
mation in PD may also be mechanistically linked to the 
development of LIDs [15]. One attractive hypothesis, for 
example, suggests that extended l-Dopa therapy may 
exacerbate the preexisting pro-inflammatory milieu, 
thereby promoting further neuron loss by shifting glial 
function more towards a damaging, rather than support-
ive role, culminating in the development and expression 
of LID [16, 17]. Support for this idea comes from the 
prior success of anti-inflammatory therapies, such as cor-
ticosterone [18] or nitric oxide synthase inhibitor [19], 
in reducing the development of LID in rat models of PD. 
Collectively, these studies indicate further exploration of 
anti-inflammatories therapies for PD patients with LID is 
warranted.
Our group has prior experience examining the thera-
peutic efficacy of putative anti-inflammatories in neuro-
degenerative disease. In particular, we have previously 
illustrated that exogenous administration of activin A 
in the CNS following an acute neurodegenerative injury 
in mice resulted in reduction in microglial numbers, 
reduced microglial activation, reduced pro-inflamma-
tory cytokine release and reduced astrogliosis [20]. More 
recently we found a significant neuroprotective effect 
of recombinant activin A treatment in the unilateral 
6-OHDA and acute MPTP mouse models of PD [21, 22]. 
Furthermore, we illustrated that activin A can reduce the 
number of microglia and astrocytes in the SNpc, which 
were previously elevated through MPTP or LPS toxicity 
[21], suggesting the mechanism underlying it’s prom-
ising effects may be anti-inflammatory. Intriguingly, a 
recent study illustrated an increase in pro-inflamma-
tory cytokine gene expression, as well as a concomitant 
up-regulation of anti-inflammatory markers, including 
activin A, in the striatum of mice with a 6-OHDA MFB 
lesion [14]. This finding, combined with our prior suc-
cess with activin A in mouse models of PD, illustrates 
activin A may be a promising therapeutic for PD, possibly 
through anti-inflammatory mechanisms. Considering the 
putative mechanistic link between LID development and 
neuroinflammation in PD it is possible this therapeutic 
promise may therefore also extend to LID.
In the following study we therefore first characterized 
the temporal evolution of neurodegeneration and mor-
tality in the 6-OHDA MFB mouse model of PD. Using 
this model we then investigated the therapeutic efficacy 
of activin A to prevent, reverse or halt the development 
of l-Dopa induced LIDs.
Results
The 6-OHDA rodent model of PD is a preclinical model 
currently used to identify promising new therapies for 
PD and related side effects, such as LIDs. In order to 
establish the progression of lesion development, mice 
were unilaterally injected with 6-OHDA or ascorbic acid 
(vehicle control) into the MFB and nigrostriatal degen-
eration was assessed over 4 weeks.
6‑OHDA injection induces cell loss in the SNpc over time
In this experiment there was a 20% mortality rate in 
6-OHDA lesioned animals, with 5 of the 25 animals 
entered into the study dying prematurely. Animals that 
underwent sham surgery had no lasting post-operative 
complications. Tissue was collected 1, 2, 3, and 4 weeks 
post 6-OHDA injection (Fig.  1a) and dopaminergic and 
total neuron numbers were quantified using stereological 
analysis of TH and NeuN positive cells, respectively, to 
assess SNpc dopaminergic neurodegeneration over time. 
Two-way ANOVA demonstrated a significant interaction 
between toxin and time on TH positive cell numbers in 
the SNpc  (F(3,32) = 10.31, p < 0.001, n = 5 per group) indi-
cating a significant effect of 6-OHDA on dopaminergic 
cell survival over time. The simple main effect of toxin 
revealed significant loss of TH positive cell numbers at 
1  (F(1,32) = 56.93, p < 0.001), 2  (F(1,32) = 171.40, p < 0.001), 
3  (F(1,32) = 203.49, p < 0.001) and 4 weeks  (F(1,32) = 203.35, 
p < 0.001) following unilateral 6-OHDA lesion compared 
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to ascorbic acid controls (Fig.  1b, c). The simple main 
effect of time after 6-OHDA treatment indicated signifi-
cant loss of TH positive cells with time  (F(3,32) = 20.55, 
p < 0.001). A Bonferroni post hoc analysis revealed a sig-
nificant difference in TH positive cells between 1 and 
2 weeks (p < 0.001), 1 and 3 weeks (p < 0.001) and 1 and 
4 weeks post lesioning (p < 0.001).
Two-way ANOVA demonstrated a significant interac-
tion between toxin and time on NeuN positive cell num-
bers in the SNpc  (F(3,32) = 7.02, p < 0.001, n = 5 per group) 
indicating a significant effect of 6-OHDA on neuronal 
cell survival over time. The simple main effect of toxin 
showed significant loss of NeuN positive cell numbers at 
1  (F(1,32) = 61.36, p < 0.001), 2  (F(1,32) = 128.82, p < 0.001), 
3  (F(1,32) = 184.03, p < 0.001) and 4 weeks  (F(1,32) = 177.59, 
p < 0.001) following unilateral 6-OHDA lesion compared 
to ascorbic acid controls (Fig.  1d, e). The simple main 
effect of time after 6-OHDA treatment indicated signifi-
cant loss of NeuN positive cells with time  (F(3,32) = 10.16, 
p < 0.001). A Bonferroni post hoc analysis revealed a sig-
nificant difference in TH positive cells between 1 and 
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Fig. 1 Time dependent loss of TH- and NeuN-positive cell populations in the SNpc following 6-OHDA, a experimental design. Mice receive 
6-OHDA or ascorbic acid (vehicle control) injection. Tissue was collected after 1, 2, 3 and 4 weeks in order to assess lesion development over time. 
Representative images of TH (b) and NeuN (d) positive neurons in the SNpc over time. Stereological quantification of the ipsilateral SNpc resulted 
in significant and progressive loss of TH (c) and NeuN (e) positive neuron counts following unilateral 6-OHDA injection. All values represent the 
mean ± standard error of the mean (SEM). *** = p < 0.001 compared to ascorbic acid, ### = p < 0.001 compared to 1 week 6-OHDA. (n = 5 per group). 
Scale bar represents 200 μm
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3  weeks (p < 0.001) and 1 and 4  weeks post lesioning 
(p < 0.001).
6‑OHDA injection induces early terminal loss in striatum
A loss of dopaminergic neurons in the SNpc has been 
shown to result in degeneration in the striatum of the 
projecting fibres from the nigral cell bodies [23], subse-
quently leading to a dopamine deficit and motor symp-
toms. DAT plays an important role for maintaining 
sufficient dopamine levels for release into the synaptic 
cleft in the striatum, and its expression has been shown 
to reduce following dopaminergic neuron loss in the 
SNpc [24, 25]. Thus, it is a useful indicator for lesion in 
the striatum following 6-OHDA. In order to confirm the 
extent of the lesion to the striatum we quantified TH and 
DAT expression in the striatum via densitometry at 1, 2, 
3, and 4 weeks post 6-OHDA administration.
Two-way ANOVA of toxin and time revealed no 
significant interaction  (F(3,32) = 0.60, p = 0.618, n = 5 
per group) of TH expression. There was a significant 
main effect of toxin  (F(1,32) = 421.73, p < 0.001) on the 
optical density of TH positive fibres in the striatum 
between 6-OHDA and ascorbic acid injected animals 
(Fig. 2a and b). However, there was no significant main 
effect of time after 6-OHDA injection  (F(3,32) = 0.39, 
p = 0.755), suggesting that the loss of TH positive fibres 
in the striatum was fully established after just 1  week 
and didn’t increase any further over time. Similarly, 
two-way ANOVA of toxin and time resulted in no sig-
nificant interaction  (F(3,32) = 0.40, p = 0.753, n = 5 per 
group) on DAT expression. There was a significant 
main effect of toxin  (F(1,32) = 1554.52, p < 0.001) on the 
optical density of DAT positive fibres in the striatum 
between 6-OHDA and ascorbic acid injected animals 
(Fig.  2c, d). However, there was no significant main 
effect of time after 6-OHDA injection  (F(3,32) = 1.27, 
p = 0.299), suggesting the loss of DAT positive fibres in 
the striatum was fully established after just 1 week and 
didn’t increase any further over time. The results from 
this study therefore  demonstrate that the modified 
6-OHDA model described by Thiele et al. [11] results in 
significant and progressive dopaminergic and total neu-
ron loss in the SNpc, as well as a loss of TH and DAT 
positive fibres in the striatum. 































































































Fig. 2 Loss of striatal terminals following 6-OHDA, Representative images of TH (a) and DAT (c) immunoreactive fibres in the striatum. Optical 
density analysis in the ipsilateral striatum resulted in significant loss of TH (b) and DAT (d) expression after 6-OHDA injection that was fully 
established 1 week after 6-OHDA injection and didn’t progress further over time. All values represent the mean ± SEM. *** = p < 0.001 compared to 
ascorbic acid. (n = 5 per group). Scale bar represents 400 μm
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Activin A levels are increased after administration 
via osmotic micropump
Prior to assessing the efficacy of activin A on LID we 
confirmed that recombinant activin A was diffusing 
to the target region when administered via an intras-
triatal osmotic micropump. Toxin and l-Dopa naive 
mice received an osmotic micropump containing either 
activin A or vehicle. Four regions, the  ipsilateral stria-
tum, contralateral striatum, midbrain and ipsilateral 
cortex, were dissected 2  days later. An ELISA was used 
to quantify  activin A  levels in these regions. Independ-
ent t-tests confirmed significantly increased activin A 
levels in the ipsilateral striatum (t = 3.907, p < 0.05, n = 5 
per group) and elevated in the neighbouring cortex 
(t = 2.144, p = 0.099, n = 5 per group). However there was 
no increase in activin A in either the midbrain (t = 0.418, 
p = 0.687, n = 5 per group) or contralateral striatum 
(t = 0.695, p = 0.507, n = 5 per group), ensuring a region 
specific diffusion of activin A via striatal micropump 
(Fig. 3).
Activin A treatment has no effect on severity or onset 
of LID
To test the efficacy of activin A as a treatment to reduce 
the severity of LID, 6-OHDA lesioned mice were ren-
dered dyskinetic with repeated l-Dopa injections over 
3  weeks. Thereafter, mice with LIDs received treatment 
with vehicle or activin A together with l-Dopa, and 
abnormal involuntary movements (AIMs) were rated for 
13 days (Fig. 4a) to investigate the ability of activin A to 
reduce the severity of LIDs.
We observed a 16% mortality rate, with 3 out of 19 ani-
mals deceasing following 6-OHDA injection. A two-way 
repeated measures ANOVA revealed no statistically 
significant effect of activin A on the severity of AIMs 
(interaction:  F(4,52) = 1.978, p = 0.112; time  F(4,52) = 5.088, 
p < 0.01; treatment:  F(1,13) = 1.071, p = 0.32, control n = 7, 
activin A n = 8; Fig.  4b). To investigate a possible effect 
of activin A on AIMs expression during a single moni-
toring session, AIM scoring was analysed at each 20 min 
interval on the final test day (Day 13). Mann–Whitney 
tests showed no differences between activin A treatment 
and vehicle at any time point after l-Dopa injections 
(20 min: U = 27.5, p = 0.955; 40 min: U = 25.5, p = 0.779; 
60  min: U = 12, p = 0.072; 80  min: U = 25, p = 0.779; 
100 min: U = 23.5, p = 0.613; 120 min: U = 24, p = 0.694; 
Fig.  4c). Furthermore, Mann–Whitney tests showed no 
changes in the expression of different subtypes (axial: 
U = 24, p = 0.694; limb: U = 12.5, p = 0.072; orolingual: 
U = 16, p = 0.189) between activin A and vehicle (Fig. 4d). 
Together these results suggest activin A has no effect on 
reducing severity of established AIMs.
We next aimed to investigate if activin A can delay 
the onset of LID. Therefore, in a second study, animals 
were randomized 3  weeks following 6-OHDA injection 
to receive either daily treatment with l-Dopa + vehicle 
or l-Dopa + activin A for 13 days (Fig. 5a). In this animal 
cohort we observed a 19% mortality rate, with 8 out of 
42 animals deceased following the 6-OHDA injection. 
A two-way repeated measures ANOVA revealed no sta-
tistically significant effect of activin A on delaying the 
onset of AIMs (interaction:  F(4,120) = 1.387, p = 0.2425; 
time  F(4,120) = 24.89, p < 0.001; treatment:  F(1,30) = 0.3608, 
p = 0.5526, control n = 17, activin A n = 15; Fig. 5b). The 
significant main effect of time on global AIMs confirmed 
the previous established LID development profile of 









































































Fig. 3 Activin A levels in the striatum, cortex and midbrain, ELISA analysis demonstrates that striatal administration via an osmotic micropump 
significantly increased levels of activin A in the ipsilateral striatum (a) and elevated levels in the ipsilateral cortex (b) but not in the contralateral 
striatum (c) or midbrain (d) when analysed 2 days later. All values represent the mean ± SEM. * = p < 0.05 (n = 5 per group)
Page 6 of 12Rentsch et al. BMC Neurosci            (2019) 20:5 
approximately 2  weeks [6]. Similar to the above experi-
ments, Mann–Whitney tests on data from the last moni-
toring session (Day 13) showed no differences between 
activin A treatment and vehicle at any time point after 
l-Dopa injections (20  min: U = 99.5, p = 0.295; 40  min: 
U = 117, p = 0.710; 60  min: U = 122, p = 0.852; 80  min: 
U = 109, p = 0.502; 100  min: U = 127, p = 1.0; 120  min: 
U = 116, p = 0.682; Fig.  5c). Furthermore, Mann–Whit-
ney tests on day 13 showed no changes in the expres-
sion of different subtypes (axial: U = 102.5, p = 0.350; 
limb: U = 121, p = 0.823; orolingual: U = 123.5, p = 0.88) 
between activin A and vehicle (Fig.  5d). Together these 
results suggest activin A has no effect on delaying 
the onset of AIMs.
Discussion
In this study we first confirmed that an updated 6-OHDA 
mouse model leads to markedly  reduced mortality. Fur-
thermore, our analysis  of neuron and fibre loss post-6-
OHDA administration extends the understanding of the 
time profile of neurodegeneration in this model. Finally, 
we are the first to report on the efficacy of activin A as 
a possible anti-dyskinetic therapy, finding no evidence to 
indicate it provides benefit, albeit with several important 
caveats, as discussed below.
An updated MFB 6‑OHDA injection protocol 
and an enhanced post‑operative care paradigm markedly 
reduces mortality in mice
Assessing the temporal profile of mortality and lesion 
magnitude following 6-OHDA injection in the MFB of 
mice provides important reference points for determin-
ing the efficacy of potential therapeutics for PD and 
LID. In the current study 81% of the cohort survived to 
21 days, confirming prior reports of markedly improved 
mortality rates using a modified injection protocol [11]. 
Thiele et al., hypothesised that a number of factors asso-
ciated with their modified injection protocol contributed 
to improved survival rates including altered stereotaxic 
coordinates, smaller injection volumes, slower infu-
sion rates and reduced cerebral damage through the use 
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Fig. 4 Activin A does not reduce severity of established LIDs, a experimental design. Mice are injected with 6-OHDA and develop a lesion over 
a 3 week period, before receiving repeated l-Dopa injections to establish AIMs during the following 3 weeks. Based on the AIMs score (Pretest) 
animals are split into 2 even groups and are implanted with an osmotic micropump containing either activin A or vehicle. Daily l-Dopa injections 
continue and AIMs are scored every 3rd day for 120 min. Activin A did not alter global AIMs score over a testing period of 13 days (b), during the 
monitoring session on the last day (c) or as a combination of axial, limb and orolingual scores during the last testing session (d). All values represent 
the mean ± SEM (control n = 7; activin A n = 8)
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approach and also used a rigorous post-operative care 
paradigm involving the provision of sugared milk (to 
stimulate appetite and prevent malnutrition), the use of 
heating pads throughout the entire protocol (to prevent 
hypothermia), and daily monitoring and prevention of 
dehydration, in line with recent recommendations [26]. 
In animals that did not survive to the endpoint (21 days) 
we noted an increased prevalence of penile prolapse, 
a finding previously observed by others [27]. To limit 
this post-operative complication throughout the study 
we provided a soft, clean bedding surface and topically 
applied an antibiotic lubricating jelly, to animals exhib-
iting signs of prolapse, to reduce further infection and 
enhance the likelihood of survival [28]. This extensive 
post-operative care paradigm likely contributed to our 
enhanced survival rate.
MFB 6‑OHDA injections in mice resulted in peak loss 
of neuron numbers after 3 weeks
Previous studies have illustrated that a significant SNpc 
lesion and dopamine deficits in the striatum are observ-
able in mice 3 weeks following MFB 6-OHDA injections, 
with both required to induce dyskinesia after repeated 
l-Dopa injections [11]. However, a prolonged analysis of 
progression of neuron and terminal loss over time using 
the modified mouse model provided by Thiele et al. has 
not yet, to the best of our knowledge, been conducted. 
In the current study we demonstrated that a unilateral 
6-OHDA administration into the right MFB resulted in 
significant and progressive dopaminergic and total neu-
ron loss in the SNpc, which takes 3  weeks to be fully 
established, before becoming stable thereafter (up to 
4  weeks). Another recent study investigated dopamin-
ergic neuron loss in mice with an MFB 6-OHDA lesion 
during the initial 2  weeks following the 6-OHDA injec-
tion [14]. In contrast to our study, the authors observed 
a more rapid loss of neurons, which may be explained 
a
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Fig. 5 Activin A does not delay the onset of LIDs, a experimental design. Mice receive a 6-OHDA injection to develop a lesion over a 3 week period, 
before undergoing an amphetamine induced rotation test to assess the lesion magnitude. Based on the rotation score animals are split into 2 even 
groups and receive an osmotic micropump filled with either activin A or vehicle. The following day repeated l-Dopa injections start and AIMs are 
scored every 3rd day for 120 min. Activin A did not alter global AIMs score over a testing period of 19 days (b), during the monitoring session on the 
last day (c) or as a combination of axial, limb and orolingual scores during the last testing session (d). All values represent the mean ± SEM (control 
n = 17; activin A n = 15)
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by their use of a higher concentration of 6-OHDA (5 ug, 
as compared to our 3  ug). Furthermore, they assessed 
neuron loss by measuring the staining intensity of TH, 
an enzyme that catalyzes the conversion of the amino 
acid l-tyrosine to l-Dopa. It has been reported that TH 
expression can decrease after toxin application [29]. 
Accordingly, an analysis of TH intensity could reflect 
a down regulation of the TH enzyme, rather than the 
loss of neurons. In our study we therefore not only ste-
reologically counted TH positive neurons, but also total 
neuron numbers in the SNpc using the neuronal marker 
NeuN. Considering we observed similar patterns in the 
counts for TH positive neuron numbers and NeuN posi-
tive neuron numbers, we are confident our results reflect 
neurodegeneration.
Administration of 6-OHDA into the MFB of  mice 
is suited for LID studies due to a consistent development 
of AIMs using this injection location. A range of other 
6-OHDA injection sites are however commonly  used 
for PD research. The most common injection site of 
6-OHDA in mice is intrastriatal, which produces a slow 
retrograde degeneration of nigrostriatal neurons over 
4–8 weeks and is an ideal model to study neuroprotective 
treatments for PD [30]. Furthermore, 6-OHDA injections 
directly into the SN result in a similarly rapid, but less 
severe lesion, when compared to MFB injected animals, 
however a detailed time course of lesion development 
has not yet been reported [10, 31, 32].
MFB 6‑OHDA injections in mice resulted in peak loss 
of striatal terminals after 1 week
Alongside neuron loss in the SNpc, 6-OHDA injection 
into the MFB also results in a loss of TH and DAT posi-
tive fibres in the striatum. In our study the loss of TH and 
DAT terminals is already fully established 1  week after 
6-OHDA surgery with no further progression over time. 
Similar studies in rats and mice with MFB lesion are in 
accordance with our results and depending on the time 
point of tissue sampling show extensive terminal loss as 
early as 72  h post 6-OHDA injection [14, 33–35]. The 
observation of terminal loss in the striatum preceding 
cell body degeneration in the SNpc is consistent with 
data from other research groups and is thought to under-
lie terminals being more sensitive to 6-OHDA toxicity 
than cell bodies [36–38].
With the results obtained from the present study 
we conclude that this modified protocol is indeed an 
improvement over earlier protocols, in that it results in 
the same magnitude of neurodegeneration within a simi-
lar timeframe, whilst markedly reducing mortality. We 
also validated that the use of a 3 week MFB lesion para-
digm ensures a complete lesion of the nigrostriatal tract.
Exogenous application of activin A has no beneficial effect 
on the timing of LID onset, or on LID severity
Dopamine replacement is the gold standard therapy for 
relieving the symptoms of PD-related movement dis-
abilities, despite the development of LIDs within a few 
years after the initiation of l-Dopa treatment. Traditional 
therapeutic investigations of LIDs have focused predomi-
nantly on pharmacologically targeting dopaminergic or 
glutaminergic signalling pathways, whilst more recent 
studies have suggested neuroinflammation as a possible 
therapeutic  target [39]. As part of these efforts, correla-
tive links have been established between the reduction of 
glial responses and reduced AIMs expression in rodent 
models of LID [18, 19]. Considering anti-inflammatory 
therapies are a novel direction for LID research, there are 
many putative anti-inflammatories that can be screened 
for efficacy in preclinical models.
In the present study we aimed to extend our prior work 
assessing the efficacy of the putative neuroprotective and 
anti-inflammatory molecule activin A in neurodegen-
erative diseases. In contrast to our prior therapeutic suc-
cesses with activin A in mouse models of PD [21, 22], we 
found no evidence in the present study that exogenously 
administered  activin A has  anti-dyskinetic capabilities. 
Specifically, we found no reduction in the severity of 
AIMs in animals with established dyskinesia, nor was 
there an effect on  the priming of LID. These findings 
were consistent across every measured time point. More-
over, the time profile in each monitoring session and the 
combination of subtypes did not differ between PBS and 
activin A treated animals.
Our study had several strengths, supporting the robust-
ness of the findings. The results of the AIMs assessment 
were consistent with previous reports [6, 27], mitigating 
the possibility our results were negative due to any tech-
nical errors with our AIMs analysis. Furthermore, we 
confirmed activin A was reaching our target region (the 
striatum), removing the possibility activin A had no effi-
cacy due to a lack of diffusion to the striatum.
Our study also has several limitations. First, we only 
included male mice and thus cannot rule out potential 
efficacy in female cohorts. Furthermore, we had initially 
predicted that a potential efficacy of activin A on LIDs 
may come about via an anti-inflammatory effect, as we 
have previously shown an anti-inflammatory and neu-
roprotective effect of activin A in mouse models of PD 
[21, 22]. Considering we were unable to detect a benefi-
cial effect of activin A on LID, we chose not to initiate an 
investigation of its anti-inflammatory properties in the 
current study. We are therefore unable to hypothesise 
the lack of efficacy was due to some failure, or partial 
failure, of its putative anti-inflammatory capabilities. We 
did however demonstrate in the present study that the 
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infused activin A was present in the brain at concentra-
tions previously shown by us to exert beneficial effects 
[21]. Additionally, although we hypothesised neuroin-
flammation plays a major role in the development of 
LIDs, we recognize a causal link between the two has not 
yet been firmly established.
It is possible therefore that activin A failed to be anti-
dyskinetic because neuroinflammation does not play a 
major role in the development and progression of LID. 
However, we perceive this as unlikely, considering the 
growing body of evidence supporting the hypothesis that 
inflammation does play a role in the development of LIDs 
[15]. There is conclusive evidence of enhanced neuroin-
flammation following 6-OHDA injection into the MFB, 
resulting in increased microgliosis and astrogliosis in the 
striatum [40]. While some research suggests the most 
significant changes in microglia and astrocyte activa-
tion occurs within a few days of the 6-OHDA injections 
and that there is a progressive reduction over time [14], 
other studies show prolonged activated states [41, 42], 
especially in astrocytes [35]. Furthermore, LID specific 
research has indicated an increased activation of micro-
glia and release of TNFα in the striatum of dyskinetic 
mice after repeated l-Dopa injections [15], strengthen-
ing the hypothesis of a neuroinflammatory milieu in the 
striatum of dyskinetic mice. Finally, we note the growing 
literature that amantadine (the only anti-dyskinetic treat-
ment available in the clinic) may partially provide benefit 
by inhibiting the inflammatory activation of microglia, 
despite long being thought to primarily exert its effects 
through weak NMDA receptor antagonism [43].
Conclusion
In conclusion this is the first study to investigate exog-
enous activin A as a therapeutic treatment in animals 
with LIDs. Although activin A failed to show an effect 
in reducing the severity or the onset of LID in this study, 
further research is required to elucidate if activin A is 
in fact not anti-inflammatory in the striatum, or if any 
potential anti-inflammatory effect is not sufficient to be 
anti-dyskinetic. Furthermore, we have established a time 
course of neuronal loss in the SNpc with subsequent loss 
of TH and DAT fibres in the striatum using an improved 
protocol of 6-OHDA injections into the MFB of mice.
Methods
Animals
Male C57BL/6  J mice (11  weeks old) were purchased 
from Australian BioResources (Mona Vale Australia). 
All animals were acclimatized for 1  week in housing of 
4–5 animals per cage, with free access to food and water, 
and in rooms maintained on a 12-h light/dark cycle. At 
the commencement of the study animals were housed 
individually and all experiments were performed during 
light hours. All surgeries were performed under a keta-
mine (8.7  mg/ml; Mavlab, Australia) and xylazil (2  mg/
ml; Troy Laboratories Pty Ltd, Australia) anaesthesia 
protocol. Tissue collection for all immunohistochemical 
experiments was obtained via cardiac perfusion under 
ketamine/xylazil anaesthesia and all tissue collection for 
ELISA experiments was obtained via cervical dislocation 
under isofluorane anaesthesia. Experiments were carried 
out in accordance with the National Health and Medi-
cal Research Council (Australia) guidelines for animal 
research and were approved by the Garvan Institute and 
St. Vincent’s Hospital Animal Ethics Committee under 
approval numbers 12/36 and 15/38.
Unilateral medial forebrain bundle (MFB) lesioning
Thirty minutes prior to surgery desipramine hydro-
chloride (Sigma Aldrich, Australia) was administered at 
10  ml/kg by intra-peritoneal (i.p.) injection. Mice were 
then anaesthetized and positioned in a stereotaxic appa-
ratus (Kopf Instruments, USA). Mice received a 0.2  μl 
injection of 15  mg/ml (total 3  μg) 6-hydroxydopamine 
hydrobromide (Sigma Aldrich, Australia) in 0.02% ascor-
bic acid in the right MFB at the following coordinates: 
AP − 1.2, ML − 1.1, DV − 5.0, relative to bregma and 
the dural surface, as previously described [11]. The injec-
tion rate of 6-OHDA (or 0.02% ascorbic acid control) was 
0.1 μl/min and the syringe was left in place for an addi-
tional 5 min post injection to allow for complete diffusion 
into the target area. The incision was sutured (Dynek, 
Australia) and animals were placed in individual cages on 
heating pads. During post-operative recovery, mice were 
provided with recovery gels and sugared milk to ensure 
adequate nutrition and hydration. One half of the cage 
was kept on heading pads for the entire study, to allow 
mice to choose their environment and to preclude hypo-
thermia. Mice were monitored daily for 3 weeks follow-
ing surgery and were injected subcutaneously with 300 μl 
glucose (5%) and 300 μl saline (0.9%) [26] if signs of dehy-
dration and malnutrition were present.
Amphetamine induced rotation test
In order to evaluate the efficacy of the lesion, mice were 
assessed for amphetamine induced rotations 3  weeks 
post lesion. Animals received an amphetamine injec-
tion (2.5  mg/kg; Sigma Aldrich, Australia, in saline i.p.) 
and were immediately placed in a clear circular cylinder 
(diameter 15 cm). After a habituation period of 10 min, 
ipsilateral and contralateral rotations were recorded for 
40 min. Total rotational activity was scored during video 
analyses. Each 360° rotation was scored, with ipsilateral 
turns scored as + 1 and contralateral turns as - 1. Results 
were expressed as ipsilateral net rotation per minute. 
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Animals with a net score of less than 2 rotation per min-
ute were excluded from the remainder of the study.
Osmotic micro‑pump implantation
Deeply anesthetised mice were placed in a stereotaxic 
apparatus. Osmotic micro-pumps (Alzet, USA) for dys-
kinesia studies (Model 1002) or for activin A availability 
studies (Model 1003D) were filled with either 49  ng/μl 
or 12.25 ng/μl respectively, for a 294 ng total daily dose 
of recombinant human/mouse/rat activin A (R&D Sys-
tems, USA) or 1 × phosphate buffered saline (PBS) con-
trol. Pumps were implanted subcutaneously at the back 
of the neck and an infusion cannula (PlasticsOne, USA) 
was attached to the micro-pump to deliver activin A to 
the right striatum at AP + 0.5, ML − 2.2, DV − 3.5 rela-
tive to bregma.
Abnormal involuntary movements (AIMs)
Mice were co-administered l-Dopa methyl ester  (6 mg/
kg; Sigma Aldrich, Australia, in saline i.p.) and bens-
erazide-HCl (12.5  mg/kg; Sigma Aldrich, Australia, in 
saline i.p.) to induce AIMs as described below in the 
experimental design section. Mice were placed individu-
ally in transparent plastic cylinders (diameter 15  cm) 
without bedding material and scored for 1  min every 
20th min during the 120  min following l-Dopa admin-
istration. Scoring was performed by an investigator 
blinded to the treatment groups. AIMs were evaluated 
according to the mouse dyskinesia scale described in 
detail previously [6, 44]. The AIMs were classified into 
three subtypes according to their topographic distribu-
tion. Axial AIMs are characterized by twisting motions of 
the neck and upper trunk towards the contralateral side 
of the lesion. Limb AIMs are rapid uncontrolled move-
ments or dystonic posturing of the contralateral forelimb 
and orolingual AIMs are movements affecting orofa-
cial muscles and contralateral tongue protrusion. AIMs 
were scored on 2 different parameters simultaneously 
on a scale of 1–4 (with 4 being the highest) based on the 
severity (amplitude scale) and the amount of time they 
were present (basic scale). A total AIMs score was then 
produced by multiplying basic score and amplitude score 
for each AIM subtype, at each monitoring period, and 
the sum of these scores is referred to as “global AIMs”.
Experimental design
Effects of activin A treatment on severity of LID
Beginning 3  weeks following 6-OHDA lesion surgery 
animals received repeated l-Dopa and benserazide injec-
tions over a 3 week period. During the final week AIMs 
were scored on 2 occasions (Pretest). Animals that failed 
to develop AIMs were excluded from the study. Based on 
the scores of the 2 testing sessions animals were equally 
divided into 2 treatment groups. On the day after the last 
pretest animals received an osmotic micropump filled 
with either activin A or sterile PBS (control). Beginning 
the day after pump implantation animals received daily 
l-Dopa and benserazide injections and AIMs expres-
sion was measured every 3rd day for a total of 5 testing 
sessions.
Effects of activin A treatment on onset of LID
Amphetamine induced rotations have been shown to corre-
late with the extent of 6-OHDA lesion, with more rotations 
indicating increased dopamine depletion [45]. Therefore, 
2  days following the amphetamine induced rotation test 
animals were equally divided into 2 treatment groups, one 
of which received a micropump filled with activin A, the 
other receiving sterile PBS (control). On the day after the 
pump implantation animals received daily i.p. injections of 
l-Dopa and benserazide and AIM were assessed every 3rd 
day to obtain a total of 5 testing sessions.
Immunohistochemistry
Anaesthetized mice were perfused transcardially 1, 2, 3, 
or 4  weeks following 6-OHDA injection using ice-cold 
PBS, followed by 4% paraformaldehyde. Whole brains 
were collected and processed as previously described in 
detail [22]. The following primary and secondary anti-
bodies were used in this study: monoclonal mouse tyros-
ine hydroxylase (TH 1:1000, Sigma Aldrich, Australia, 
cat # T2928), polyclonal rabbit anti-TH (1:1000, Merck 
Millipore, Australia, cat # AB152), monoclonal mouse 
neuronal nuclei (NeuN 1:500, Merck Millipore, Australia, 
cat # MAB377), monoclonal rat dopamine transporter 
(DAT 1:1000, Merck Millipore, Australia, cat # MAB369), 
biotin-labeled antibodies (1:250, Abcam, Australia, cat 
# AB6813; ThermoFisher Scientific, Australia, cat # 
B-2770). Immunolabeling was detected with 3,3′-Diam-
inobenzidine (DAB, Abacus) or Nova-Red (Abacus) 
according to manufacturer’s instructions.
Stereology
SNpc cell populations were quantified using the optical 
fractionator method and Stereo Investigator 7 software 
(MBF Bioscience, USA), as previously described [22]. The 
investigator was blinded to experimental groups during 
stereological counting.
Densitometry
TH-positive and DAT-positive fibres in the striatum 
were analysed using optical densitometry at the fol-
lowing coordinates relative to bregma: − 0.24  mm, 
− 0.48 mm, − 0.72 mm, and − 0.96 mm, using Image Pro 
Plus 6.0 software (Media Cybernetics, USA) as previously 
described [22].
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Activin A ELISA
Toxin and l-Dopa naïve mice were sacrificed by cervical 
dislocation 2  days following activin A pump implanta-
tion and the ipsilateral striatum, contralateral striatum, 
midbrain (substantia nigra + ventral tegmental area) and 
ipsilateral cortex were rapidly dissected. Tissue homoge-
nates and protein quantification were performed as pre-
viously described [21]. Activin A levels were measured 
via an ELISA (Quantikine Activin A assay, R&D systems, 
USA) according to manufacturer’s instructions. All sam-
ples were analysed in duplicate on the same ELISA plate 
and the average intra-assay coefficient of variation (CV) 
was 7.9%.
Statistics
All statistical analyses were performed using IBM SPSS 
Statistics version 25 (SPSS Inc., USA). Shapiro–Wilk 
tests were performed on all data sets to assess normal-
ity, before analysing data either with parametric or non-
parametric tests. All data included in the time course of 
lesion development was assessed by two- way ANOVA 
followed by Bonferroni post hoc analysis. Data obtained 
from LID studies were analysed with two- way repeated 
measures ANOVA or Mann–Whitney tests, while data 
acquired with activin A ELISA were analysed using inde-
pendent t-tests  (Additional file 1).
Additional file
Additional file 1: Datasets. Raw data used for Figs. 1, 2, 3, 4 and 5.
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